Ewing's sarcoma (EWS) cells accumulate elevated steady-state levels of poly (ADP-ribose) polymerase (PARP) mRNA and protein. To understand the molecular mechanisms underlying PARP upregulation, we cloned and analysed the 5'-¯anking region of the PARP gene from EWS cells. Nucleotide sequence analysis demonstrated no variations in the PARP promoter region in EWS cells. The PARP promoter encompasses multiple binding motifs for the ETS transcription factor. We have also observed that there is a coordinated up-regulation of the expression of both PARP and ETS1, relative to cells of other human tumor types expressing lower levels of PARP. Transient coexpression of ETS1 in EWS cells resulted in a strong enhancement of PARP-promoter activity. The participation of ETS in the regulation of PARP gene expression was further demonstrated in EWS cells stably transfected with Ets1 antisense cDNA constructs. Antisensemediated down-regulation of endogenous ETS1 resulted in the inhibition of PARP expression in EWS cells, and sensitized these cells to ionizing radiation. These data provide support for ETS regulation of PARP expression levels, and implicate ETS transcription factors in the radiation response of EWS cells.
Introduction
Poly (ADP-ribose) polymerase (PARP, EC 2.4.2.30) is a chromatin-associated enzyme which catalyzes the transfer of the ADP-ribose moiety from NAD to itself and other nuclear acceptor proteins. The catalytic activity of PARP is strictly dependent on the presence of strand breaks in DNA, and is modulated by the level of automodi®cation. It has been suggested that PARP-dependent protein modi®cation has a functional role in important cellular processes such as DNA replication, recombination and repair, cell cycle regulation, cell dierentiation and neoplastic transformation (reviewed in Cleaver and Morgan, 1991).
However, despite numerous studies on the function of PARP in mammalian cells and recent advances in the molecular genetics of the PARP encoding gene, very little is known about mechanisms for regulation of PARP gene transcription.
The human gene for PARP was localized to chromosome 1 (q41 ± q42) (Cherney et al., 1987) and its 5'-regulatory region was isolated from normal human liver and lymphoid cells (Ogura et al., 1990; Yokoyama et al., 1990; Oei et al., 1994) . The PARP promoter exhibits features typical of TATA-de®cient, G+C rich class of promoters (Ingolia et al., 1986) . Genes controlled by this type of promoter include many that are highly regulated and functionally important (reviewed in Ackerman et al., 1993) . Several lines of evidence have suggested that PARP gene expression is also regulated at the level of transcription. First, previously recognized features of the PARP promoter have indicated a number of possible transacting factors including the presence of dyad symmetry units, SP1, AP-2 and YY1 transcription factor binding sites (Ogura et al., 1990; Yokoyama et al., 1990; Oei et al., 1997) . Next, the induction of PARP gene expression in response to cAMP and phorbol esters has been demonstrated in vitro and in vivo (Yokoyama et al., 1990) . Further, changes in the levels of PARP mRNA have been shown during cell dierentiation , cell cycle progression (Wein et al., 1993) , lymphocyte activation (Negroni and Bertazzoni, 1993) and liver regeneration (Cesarone et al., 1990) . More recently, a mechanism of PARP gene autoregulation has been proposed, involving the speci®c interactions between PARP protein and cruciform structures located in the distal region of the PARP promoter (Oei et al., 1994) . Although these data suggest the existence of regulatory factors for PARP gene expression, endogenous PARP transactivators have not been identi®ed to date.
PARP gene expression is maintained at relatively low levels in most of the human tissues suggesting the existence of intrinsic mechanisms for the autoregulation of endogenous content of PARP protein . In contrast, EWS cells accumulate PARP mRNA, protein and polymerase activity (Prasad et al., 1990) at levels that, with the exception of yeasts (Avila et al., 1994) , would cause the death of other cell types. Therefore, EWS cells represent a unique model to investigate PARP transcriptional regulation with regard to the identi®cation of the transcription eectors responsible for the unusually high levels of PARP in these primitive neuroectodermal tumor cells. Recently, we utilized EWS cells to demonstrate that the dbl proto-oncogene participates in mechanisms which regulate the endogenous levels of PARP in mammalian cells (Velasco et al., 1995) .
About 85% of the Ewing family of tumors carry the t(11;22)(q24;12) translocation which results in the oncogenic conversion of several members of the ETS family of transcription factors, such as FLI 1, ERG, ETV 1 (Delattre et al., 1992; Sorensen et al., 1994 : Jeon et al., 1995 . These ®ndings suggest that some ETS proteins play an important role in the biology of Ewing's sarcomas. In the present report we describe the presence of previously unrecognized ETS-binding sites surrounding the transcription start site in the PARP promoter, and show that the ETS1 transcription factor transactivates the PARP promoter in vitro and that PARP gene expression can be modulated in cells stably transfected with antisense Ets1 cDNA. Our data also demonstrate that down-regulation of endogenous ETS1 has a signi®cant impact on the response of EWS cells to ionizing radiation.
Results

Functional analysis of the PARP promoter from EWS cells
In order to understand the mechanism responsible for the unusually high levels of PARP expression in EWS cells, we used DNA from the A4573 cell line to clone a 1101 bp genomic fragment that contains the 5'¯anking region (from 7899 to +202) of the PARP gene ( Figure 1a ). The PARP promoter fragment was inserted upstream of the bacterial chloramphenicol acetyl-transferase (CAT) gene, and the resulting construct (pC1.11) was transfected into EWS A4573 cells. These cells exhibit endogenously high levels of PARP mRNA transcript and express PARP protein constitutively at high levels (Prasad et al., 1990) . As shown in Figure 1c , the cloned promoter fragment was capable of eciently driving reporter gene expression in EWS cells, yielding levels of CAT activity approximately 16-fold above those detected in extracts of cells transfected with a control, promoterless CAT vector (pCAT). Nucleotide sequence analysis of the cloned fragment revealed no remarkable dierences with the sequences reported for PARP promoter regions isolated from normal human cells (Ogura et al., 1990; Yokoyama et al., 1990) . These data suggested that the enhanced levels of PARP in EWS cells relative to normal cells could be due to transcriptional upregulation of the PARP promoter rather than to sequence dierences within the PARP 5'-regulatory region.
To further analyse the EWS PARP regulatory sequences, a series of 5'-and 3'-deletion mutants were generated and fused to the CAT gene in the reporter vector (Figure 1d ), and the resulting constructs were transfected into EWS A4573 cells. As indicated in Figure 1d , removal of sequences from 7899 to 7650 resulted in a modest decrease in CAT activity indicating the presence of a weak positive element within this region. However, deletion of the next 555 nucleotides (pDS/E) not only restored the CAT activity but displayed an approximately 50% more ecient transcriptional activity than the entire fragment (pC1.11), suggesting that the 7650 to 795 region may negatively control PARP promoter activity. These results indicated that the major PARP promoter region (`core') resides in the region extending from 795 to +156 on the PARP gene. Indeed, these regions contain the major transcription initiation site, SP1 binding sites, CpG-rich islands, consensus sequences for binding of AP-2 and elements responsive to cAMP and phorbol ester (Ogura et al., 1990; Yokoyama et al., 1990) . The analysis of 3' deletions of the PARP regulatory region revealed a consistent decrease in CAT activity as the promoter sequences were deleted from +156 to +35. These data suggested that the region downstream of the transcription start site is recognized by transactivating factors.
Computer analysis of the PARP promoter region revealed ®ve putative ETS-recognition sites, denoted as E1-E5 (Figure 1a) , that matched perfectly the binding core motif (Figure 1b) reported for ETS proteins (Boulukos et al., 1989; Wasylyk et al., 1993) . Of particular importance is the fact that these ETSbinding motifs are located within the regions containing positive and negative control elements (Figure 1d ). These results suggested the potential involvement of members of the ETS DNA-binding proteins in the transcriptional regulation of the expression of the PARP gene. Figure 2a shows that, in agreement with previous reports (Prasad et al., 1990) , EWS cell lines (A4573, TC 106, SK-ES-1) express enhanced levels of PARP protein relative to other human tumor cell lines tested. Previously we reported that EWS cell lines also contain high levels of PARP mRNA (Thraves et al., 1989; Prasad et al., 1990; Velasco et al., 1995) and suggested the possibility that the up-regulation of PARP in these cells was a transcriptional eect. Furthermore, treatment of EWS cells, A549 human lung adenocarcinoma cells and SQ-20B cells with actinomycin D followed by Northern analysis of RNA prepared after various treatment periods demonstrated that increased PARP mRNA stability is not the determinant of the elevated PARP expression levels in EWS cells (data not shown). Reasoning that transcriptional control may be responsible for PARP upregulation in EWS cells, we transiently transfected the EWS cell-derived PARP promoter-CAT construct into squamous carcinoma SQ-20B cells expressing low levels of PARP, to establish whether the cellular background would modify its transcriptional activity. As shown in Figure 2b , the transcriptional activity of the PARP promoter from EWS cells was approximately twofold greater in EWS cells than in SQ-20B cells. These results strongly suggested that transcriptional control, most likely by transcription factor availability, is the main determinant for PARP expression levels in dierent cell types.
Co-regulated expression of PARP and ETS1 proteins in EWS cells
Taking in account the presence of multiple ETSbinding sites (Figure 1a (Ogura et al., 1990) . The coding sequence beginning with the translational initiation codon ATG is shown in uppercase. Putative motifs matching consensus binding sites for ETS transcription factor (b) are boxed and denoted as E1-E5. (c) The PARP promoter is active in EWS cells. A4573 cells were transfected with pSV-CAT vector containing SV40 promoter (1); pCR II-CAT, the promoterless CAT gene (2); pCl.11 construct with PARP promoter placed in front of CAT gene (3). After transfection (48 h) the cells were harvested and CAT activities were assayed. Acetylated and nonacetylated forms of chloramphenicol were separated by thin layer chromatography and visualized by autoradiography. Experiments were repeated three times with essentially the same results. Representative autoradiogram is shown. (d) A schematic representation of the human PARP promoter (top). Filled square boxes indicate the positions of putative ETS motifs. Numbers are relative to the upstream transcription initiation site (arrow). PARP promoter progressive deletional analysis (bottom). The PARP promoter-CAT construct, pCl.11, was made by cloning the DNA fragment 7899 to +156 in front of the CAT reporter gene. 3' deletion constructs were generated by treatment with ExoIII and 5' deletions were created by BstXI and SmaI restriction enzymes digestion (respective sites are indicated) and ligations. Position of 5' and 3' ends of the deletion mutants are shown according to the +1 reference. Transfections and reported gene assays were performed as described in Materials and methods. Relative CAT activity directed by the longest upstream sequence (7899 to +156) was designated as 100%. All values were normalized for b-galactosidase activity. Values are mean+s.d. from three separate experiments, each done in duplicate et al., 1994) we asked whether ETS proteins were also overexpressed in EWS cells. Results of Western blot analysis (Figure 2a) showed that the EWS cell lines consistently expressed ETS1 at high levels which correlated well with the levels of PARP in the same cells. These results suggested the existence of a positive co-regulation for the expression of the two proteins in EWS cells. Consequently, we hypothesized that members of the ETS family of DNA-binding proteins may participate in the upregulation of PARP gene expression in EWS cells.
Transactivation of the PARP promoter by ETS1 in EWS cells
In order to analyse the ability of ETS proteins to activate the human PARP promoter, reporter plasmids in which CAT expression was driven by either the homologous (EWS cell-derived, pC1.11) or heterologous (normal ®broblast-derived, pBal-CAT) PARP upstream sequences were cotransfected into A4573 cells with an ETS1 expression vector, pSV40-ETS1. Control experiments were performed by cotransfecting A4573 cells with empty vector. As shown in Figure 3 , the CAT activity of both PARP promoter constructs was markedly stimulated by expression of exogenous ETS1. These data indicated that ETS-binding sites can mediate, directly or indirectly, the transactivation of PARP promoter. The fact that pBal-CAT (71776 to +70) showed greater transcriptional activity may re¯ect the presence of additional functional ETS-binding sites in this construct, in the region between 7899 to 71776. Although the possibility that other cis-acting elements residing within this region may cooperate with ETS for more ecient stimulation of the promoter cannot be ruled out.
Regulation of PARP gene expression by ETS in vivo
To further understand the regulation of PARP gene expression by ETS protein at the cellular level, we stably transfected a construct for the expression of the full-length human Ets1 cDNA, in the antisense Figure 3 ETS1 stimulates the PARP promoter activity in transiently transfected EWS cells. A4573 cells were co-transfected with ETS1 expression plasmid (pSV40-ETS1) and either homologous reporter construct (pCl.11) or heterologous PARP promoter-CAT plasmid (pBal-CAT). Total amounts of DNA transfected were kept constant using the empty vector pSG5. CAT reporter gene activity was normalized for b-galactosidase and expressed relative to activity of respective PARP constructs in the absence of exogenous ETS1 that was arbitrary set at 1.0. Values are the mean of at least three independent experiments, each performed in duplicate. Standard deviations are indicated Figure 2 (a) Expression levels of PARP and ETS1 proteins in dierent human tumor cell lines. Total cellular proteins were extracted from logarithmically growing EWS sarcoma (A4573, TC106 and SK-ES-1), cervical carcinoma (HeLa), lung carcinoma (A4573) and laryngeal squamous carcinoma (SQ-20B) cell lines. Samples containing equal amount of protein (25 mg) were resolved on SDS-gradient (4 ± 20%) polyacrylamide gels and immunoblotted with anti-PARP or anti-ETS1 monoclonal antibody. Immunodetection of GAPDH was used as a reference for quantitative loading of samples. (b) PARP promoter-CAT construct (pCl.11) was transiently transfected into cells expressing high (A4573) or low (SQ-20B) endogenous levels of PARP protein. Reporter gene activity was assayed 48 h after transfections as described in Materials and methods. CAT activity in A4573 cell extracts was arbitrarily taken as 100%. Each value represents the average of three to four independent transfections, each done in duplicate orientation, into EWS A4573 cells. To avoid clonal heterogeneity eects, we used pooled populations of transfectants in these experiments. Results from Western analyses (Figure 4a) showed that all three independently obtained cellular pools (ETS-AS-1, 2 and 3) express approximately twofold lower levels of ETS1 relative to cells transfected with the empty vector (A4573 neo). Most importantly, this inhibition of ETS1 expression was paralleled by a down-regulation of PARP expression: the extent of ETS1 expression in the antisense-transfected cells directly correlated with their intracellular PARP content as evidenced by densitometric analyses of autoradiograms (Figure 4b ). These data demonstrated that alterations of the endogenous levels of ETS1 may impair the transcriptional regulation of PARP gene expression. The reverse experiment designed to further increase the PARP levels in EWS cells using sense Ets1 cDNA was not informative due to the premature death of the transfected cells before colonies could be expanded.
These data demonstrated that, although higher than for other cells, EWS cells also have a threshold of PARP expression beyond which they do not survive, as described for other types of mammalian cells Jorgensen et al., 1993) .
Inhibition of ETS1 expression enhances growth retardation of irradiated EWS cells
We next studied whether inhibition of ETS1 and PARP expression would have any in¯uence on the proliferation of EWS cells and their response to DNA-damaging treatments. Based on the results shown in Figure 4 , the ETS-AS-1 cell population was selected for this study. These cells did not exhibit visible morphological alterations as observed by phase-contrast microscopy (data not shown) but expressed lower levels of PARP and ETS1 proteins (Figure 4) . When the growth kinetics of A4573 cells transfected with control neo vector or with antisense Ets1 containing plasmids were compared, no signi®cant dierences were found (data not shown). In contrast, the ionizing radiation-induced growth inhibition was noticeably enhanced in the case of antisense-Ets1 bearing transfectants ( Figure 5 ). Previously, we had reported that ionizing radiation induces a pronounced, but reversible G 2 -M phase cell cycle arrest followed by induction of programmed death of EWS cells (Soldatenkov et al., 1995) . Therefore, it is highly suggestive that perturbations in the radiation-induced block of cell cycle progression and/or modulation of apoptotic pathways could cause the observed eects of Ets1 antisense cDNA expression on the response of EWS cells to ionizing radiation. Antisense ETS1 expression enhances radiation-induced growth inhibition in EWS cells. Logarithmically growing A4573 cells transfected with neo vector or with antisense-Ets1 construct were irradiated at a dose of 7 Gy. Cells were stained with MTS tetrazolium compound at indicated times and number of live cells were determined based on absorbance value (490 nm) as described in Materials and methods. Inhibition of cell growth is expressed as a ratio of absorbance at 490 nm in control (untreated) to irradiated cells at each time-point. Absorbance ratio for A4573 neo and ETS-AS-1 cell populations immediately after irradiation was taken as 1.0 Discussion Whereas PARP is expressed at low levels in most of mammalian tissues examined De Murcia et al., 1991) , Ewing's sarcoma tumor cells accumulate elevated levels of PARP mRNA, protein and polymerase activity (Prasad et al., 1990) . We have cloned and characterized the 5'-¯anking region of the PARP gene from EWS (A4573) cells. Our data show that PARP promoter strength correlates with the high levels of PARP mRNA and protein expression in EWS cell lines (Prasad et al., 1990; Velasco et al., 1995) and strongly suggest that transcription factor availability, rather than nucleotide sequence dierences or mRNA stability, is the main determinant for PARP expression levels. Previous studies also indicated that PARP is an inducible gene (Cesarone et al., 1990; Negroni and Bertazzoni, 1993) and that its promoter responds to extracellular signals such as cAMP and phorbol esters (Yokoyama et al., 1990) . However, endogenous PARP transactivators have not been identi®ed to date. Our results indicate that ETS transcriptional factors are capable of transactivating the PARP gene.
The ETS multigene family encodes a class of eukaryotic transcription factors which share a highly conserved DNA-binding sequence, referred as the ETS domain. ETS protein binding sites contain an invariant core motif C/A GGA A/T¯anked by variable sequences which contribute to the DNA binding selectivity of the family members (reviewed in Wasylyk et al., 1993) . We found that one remarkable feature of the PARP gene promoter is that it contains multiple ETS motifs. Although the relevance of each one of these ETS-binding sites remains to be determined, their location within regions that are capable of mediating transcriptional activity of the PARP promoter suggested a functional role for these motifs. This suggestion was further strengthened by data from cotransfection experiments showing that exogenous ETS1 is capable to transactivate in vitro promoter constructs encompassing dierent lengths of the PARP 5'-sequences from normal or tumor cells. Moreover, using antisense cDNA for Ets1 we demonstrated the inhibition of intrinsic PARP gene expression in EWS cells. The latter approach has been successfully used to identify relevant ETS target genes in lymphoid cells (Romano-Spica et al., 1995) .
Recent advances in molecular genetics have revealed that TATA-de®cient and G+C-rich promoters are prevalent and control highly regulated genes (reviewed in: Ackerman et al., 1993) and that ETS family members may have a primary role in the formation of the initiation complex on core promoters lacking the TATA sequence (reviewed in: Wasylyk et al., 1993) . Moreover, ETS motifs are frequently located in the vicinity of the transcription start site in a number of promoters that lack a TATA element, including the genes encoding DNA polymerase a and b (Pearson et al., 1991; Yamaguchi et al., 1988) , thymidilate synthetase (Jolli and Johnson, 1991) , von Willebrand factor (Schwachtgen et al., 1998 ), Ets2 (Mavrothalassitis et al., 1990 , the tumor suppressor gene Maspin (Zhang et al., 1997) and number of myeloid speci®c genes (reviewed by Moreau-Gachelin, 1994) . It seems that PARP can be added to this group of genes because it exhibits features typical of TATA-de®cient promoters and has consensus ETS motifs close to the major initiation sites.
Although co-transfection experiments demonstrated trans-activation of the human PARP promoter by an ETS1-expressing plasmid, the identity of proteins involved is not yet clear, and there is a potential role for other factors interacting with ETS1 in PARP gene regulation. The following possibilities for such interplay should be considered. First, the functions of ETS proteins are often associated with the binding of cooperative regulatory proteins which could stabilize the interactions between the ETS and DNA (Petersen et al., 1995) and are necessary for speci®c gene transactivation in particular cell types (reviewed in: Papas et al., 1997) . Second, the oncogenic conversion of Fli-1, Erg and other Ets related genes via gene fusion has been reported in EWS cells (Delattre et al., 1992; May et al., 1993; Sorensen et al., 1994; Jeon et al., 1995; Peter et al., 1997) . Rearrangement of these genes may result in the alteration of their transcription activator properties, For instance, it has been shown recently that EWS acts as a regulatory domain for the transcriptional activator function of the EWS/FLI1 chimeric protein (Ohno et al., 1993) . The EWS domain may be involved in protein-protein interactions with other factors and thus aect their sequence speci®city. Furthermore, these aberrant transcription factors may transactivate dierent genes as it was observed in the case of oct-1 and oct-2 (Robertson, 1988) . Since many of the Ets genes are regulated by members of their own family (reviewed in Papas et al., 1997) it would be of interest to explore the possibility for such interactions in control of PARP gene expression. Third, the Ets1 gene is capable of regulating its own expression (Seth and ) and the ETS1 protein itself is subject to several types of post-translational modi®cations that aect its DNA-binding activity (reviewed in Bassuk and Leiden, 1997) . Therefore, further studies are required to identify factors that could co-operate with ETS in controlling PARP gene expression.
Most of the EWS tumors carry the t(11;22)(q24;q12) translocation resulting in expression of fused EWS/ FLI-1 protein, including the A4573 cell line used in the present study (Yee et al., 1990; Delattre et al., 1992) . The suppression of EWS/FLI-1 transcription using antisense cDNA or dominant-negative constructs resulted in growth inhibition of EWS cells in vitro indicating the involvement of this chimeric oncoprotein in regulation of cell proliferation (Kovar et al., 1996) . In contrast, down-regulation of ETS1 expression did not cause cell growth retardation indicating that ETS1 is not indispensable for A4573 tumor cell proliferation. These data are in line with the observation that translocation involving Fli-1 does not aect the expression of neighboring Ets1 in EWS cells. Moreover, the Ets1 gene has not been assigned yet to a tumor speci®c chromosomal breakpoint (reviewed in Bassuk and Leiden, 1997) . It is tempting to speculate that dysregulated expression of Ets1 does not alter the growth potential of EWS cells. However, when EWS cells were treated with ionizing radiation the functional consequences of ETS1 inhibition became pronounced. We attributed this eect to the co-regulated inhibition of the expression of PARP, an enzyme implicated in DNA-repair (Satoh and Lindahl, 1992) . This suggestion is consistent with ®ndings by others that PARP levels are not rate limiting for the proliferation of normal (undamaged) cells and that downregulation of PARP expression results in increased cell susceptibility to DNA-damaging treatments (Ding et al., 1992; Wang et al., 1995; KuÈ pper et al., 1995; Schreiber et al., 1995) . Another explanation may involve the potential role of the ETS protein itself in the radiation response of EWS cells. The extent of radiation-induced cell growth inhibition is an integrative parameter re¯ecting the decrease in cell number due to a block of cell cycle progression and an induction of programmed death of EWS cells (Soldatenkov et al., 1995) . Interestingly, ETS proteins play a role in regulating genes involved in both cell cycle progression and programmed cell death including cdc2, jun B, c-fos, c-myc, Rb, p53 and bcl-2 (reviewed in Bassuk and Leiden, 1997) . In addition, the function of ETS1 in the regulation of apoptosis has been recently demonstrated in lymphoid (Bories et al., 1995) and colon cancer cells (Huang et al., 1997) .
In conclusion, ETS proteins appear to play an important role in the biology of Ewing's sarcomas. Members of the family such as FLI-1, ERG and ETV1 are implicated in malignant transformation of the enigmatic Ewing tumor-precursor cells (Delattre et al., 1992; Sorensen et al., 1994 : Jeon et al., 1995 Kovar et al., 1996) . Our report demonstrates that another member of the ETS superfamily, ETS1, can function directly or indirectly as a transcriptional regulator of PARP. Although further studies are required to understand the role of other transcriptional factors and cis-acting elements in the regulation of the PARP gene, the ®ndings reported here may provide an approach for the manipulation of PARP levels in human tumor cells and, therefore, for the modulation of their response to ionizing radiation and DNAdamaging drugs to improve the outcome of anti-tumor therapies.
Materials and methods
Cell culture and irradiation
Ewing's sarcoma cell lines A4573, TC106 (kindly provided by Dr T Kinsella, University of Wisconsin, Madison, USA) and SK-ES-1 (purchased from ATCC, Rockville, MD, USA), were maintained in Eagle's minimal essential medium (GIBCO) supplemented with 10% fetal bovine serum, 1% L-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin at 378C in an atmosphere of 5% CO 2 in air. HeLa cervical carcinoma and A549 lung carcinoma cells (from ATCC, Rockville, MD, USA) were cultured in essentially the same medium as EWS cell lines. Human laryngeal squamous carcinoma SQ-20B cells (a gift from Dr R Weichselbaum, University of Illinois, Chicago) were grown and maintained in complete Dulbecco's modi®ed Eagle medium (GIBCO) as described (Soldatenkov et al., 1997) . All irradiations were performed at room temperature, in air, using a 137 Cs source in a`JL Shepard MARK I' laboratory irradiator at a dose rate of 3.85 Gy/min.
Promoter cloning and construction of CAT reporter plasmids
A fragment of 1101 bp encompassing the PARP transcription start site was ampli®ed by PCR of genomic DNA from A4573 cell line. The primers, 5'-CTGATAGCAACAGGTG-CAGTCA-3' (upstream) and 5'-CTCGACTCGATA-GAGCTTATCC-3' (downstream) were designed according to the reported sequence data of the PARP 5' region from normal human cells (Ogura et. al., 1990; Yokoyama et al., 1990) . PCR reactions were performed in 100 ml volume using 2.5 units of AmpliTaq DNA polymerase (Perkin Elmer Cetus) according to manufacturer's speci®cations, with denaturing at 968C for 1 min, annealing at 588C for 1 min, and extension at 728C for 2 min. The resulting PCR product was directly cloned in pCR II vector (TA cloning kit, Invitrogen) and sequenced to verify its ®delity. A HindIIIchloramphenicol acetyltransferase (CAT) gene cassette (Pharmacia) was inserted into the unique HindIII site of pCR II-5' PARP, and clones with CAT in the sense transcriptional orientation relative to the PARP 5' sequences (pCR II-5' PARP-CAT) were selected for the construction of deletion mutants.
Progressive 3'-deletions ( Figure 1d ) were generated by initial digestion of the pCR II-5' PARP-CAT construct with exonuclease III, followed by treatment with S1 nuclease and recircularization using the Erase-a-Base system (Promega). Brie¯y, pCR II-5' PARP-CAT was linearized with BamHI and KpnI which cleave between the PARP sequences and the CAT gene, the BamHI site being proximal to the 3' end of the PARP sequences. Treatment with ExoIII resulted in the progressive shortening of the linearized DNA only from the unprotected 5' overhang of the BamHI end, whereas the KpnI 3' overhang remained protected. Reaction products from timed ExoIII deletions were treated with S1 nuclease and the Klenow fragment of DNA polymerase to generate blunt ends followed by religation. The resulting 3' deletion constructs (pCl.11, pCl.23, pCl.31 and pCl.54) were sequenced to con®rm the site of deletion and to verify their selection for transient transfections. The 5' deletions ( Figure 1d ) were created by taking advantage of unique restriction endonuclease sites present in the multiple cloning site of the pCR II vector (EcoRV and BstXI) and the existence of ligation compatible sites (SmaI and BstXI) within the 5' PARP sequences. Cleavage of pCl.11 with these enzymes and removal of the EcoRV ± SmaI and BstXI ± BstXI fragments followed by self-ligation of the plasmid resulted in the generation of the 5' deletion constructs, pDS/E and pDBstXI, respectively. The pBal-CAT plasmid that contains the 5'-anking region (nucleotides 71776 to +70) of the PARP gene isolated from human leukocyte genomic DNA was kindly provided by Dr T Ogura (National Cancer Center Research Institute, Chiba, Japan). ETS1 expression vectors (pSG5-neo) containing the entire Ets1 ORF (1.9 kb) in sense (pSV40-ETS1) or antisense (pSV40-AS ETS1) orientation were a gift from Dr T Papas (Medical University of South Carolina).
Transient transfections and reporter gene assay
DNA transfections were carried out using an activateddendrimer reagent (Superfect, Qiagen) essentially as described by the manufacturer. One day prior to transfection, 2610 5 cells were plated into 60 mm culture dishes. The 5' PARP-CAT plasmid DNAs (4 mg) and the pSV-b-Gal vector (Promega, 1 mg), as an internal control, were transiently transfected into A4573 or SQ-20B cells using a ratio of DNA to transfection reagent of 1 : 6, for 5 h, followed by replacing the medium containing DNA complexes with complete growth medium. pCR II-CAT (promoterless) plasmid and pSV-CAT vector containing SV40 promoter (Promega) were used as negative and positive controls for transient CAT expression assay. Cytoplasmic extracts were prepared from A4573 or SQ-20B cells 48 h after transfection using the reporter lysis buer (Promega). The activity of b-galactosidase was determined by colorimetric assay (Promega) and extracts containing equivalent amounts of b-galactosidase activity, to ensure corresponding transfection eciencies, were then used for the CAT assays. The CAT activity was determined using the liquid scintillation counting of n-butylated [ 14 C] chloramphenicol and by thin layer chromatography on silica gel plates as described previously (Albor et al., 1994; Hodge et al., 1995) . In the co-transfection experiments, cells were transfected with 4 mg of 5' PARP-CAT plasmids (pCl.11 or pBal-CAT), with 4 mg of pSG5-based expression vector for human ETS1 (pSV40-ETS1) and 1 mg of pSV-b-Gal vector as internal standard. The total amount of DNA transfected was held constant to 9 mg with the pSG5 empty vector. Each experiment was repeated at least three times, each in duplicate, with independent plasmid preparations to assess reproducibility.
Stable transfections
A4573 cells were stably transfected with the neomycin selectable pSG5 plasmid containing the human Ets1 cDNA in the antisense orientation or with control, neomycinresistant expression vector pZIP-neo-SVX (Cepko et al., 1984) using`Superfect' transfection reagent (Qiagen) according to manufacturer's protocols. Brie¯y, cells (2.0610 5 ) were plated into 60 mm tissue culture dishes and transfected next day with 4 mg of pSV40-AS ETS1 or pZIP-neo-SVX DNAs cells using a ratio of DNA to`Superfect' reagent of 1 : 6. The transfection medium was replaced 5 h later with complete growth medium and the cells were incubated for 48 h to allow for expression of neomycin-resistance, followed by replating into selective medium containing 250 mg/ml G418 (Geneticin; GIBCO). The G418-resistant colonies from each replicated experiment were pooled to form polyclonal cell populations and were routinely maintained in medium containing 100 mg/ml G418.
Proliferation assay of stably transfected cells
Growth characteristics of stably transfected A4573 cell populations were assayed by a colorimetric method using the tetrazolium compound, MTS (Promega). Exponentially growing cells were seeded in 96 well tissue culture plates at density of 1610 4 cells per well and maintained for 24 h to allow for cell attachment to plastic prior to radiation treatment. Cells irradiated at 7 Gy and control unirradiated cells were incubated at 378C in humidi®ed 5% CO 2 for up to 5 days. The MTS reagent was added to the wells for 2 h and its bioreduction by cells was measured as absorbance at 490 nm using a 96 well plate reader (Bio-Tek Instruments Inc.).
Western immunoblot analyses
Logorithmically growing cells were washed twice with cold PBS and lysed at 48C for 30 min in buer: 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 100 mM NaCl, 1 mM phenylmethylsulfonyl¯uoride, 20 mg/ml aprotinin and 20 mg/ ml leupeptin. Insoluble material was removed by centrifugation at 48C for 30 min at 16 000 g and protein concentrations were determined using the`Micro BCA protein assay' (Pierce). Cellular proteins (25 ± 30 mg/sample) were resolved on SDS-4-20% gradient polyacrylamide gels (Bio-Rad) and transferred to Immobilon-P (Millipore) membranes. Immunodetection of immobilized antigens was performed as described previously (Soldatenkov et al., 1995) . Brie¯y, the membranes were blocked with 5% bovine serum albumin in TBST (Tris buered saline with 0.1% Tween 20) and probed with either anti-PARP (1 : 10 000, Enzyme Systems Products) or anti-ETS1 (1 : 1000, Transduction Labs) monoclonal antibody followed by detection of speci®c proteins by thè ECL method' according to the manufacturer's protocol (Amersham). Equal sample loading was con®rmed by reprobing the same blots with a rabbit polyclonal antiserum against glyceraldehyde 3-phosphate dehydrogenase, GAPDH (1 : 5000, Trevigen). Densitometric analyses were performed using an Alpha Imager 2000 documentation system (Alpha Innotech Corp.).
